The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 29, No. 1, pp. 25-29.
© 1995 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holdsworth, M.
Right arrow Articles by Duncan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holdsworth, M.
Right arrow Articles by Duncan, M.


Research Articles

Continuous midazolam infusion for the management of morphine-induced myoclonus

MT Holdsworth, VR Adams, CM Chavez, LJ Vaughan, and MH Duncan

OBJECTIVE: To describe a patient with morphine-induced myoclonus treated with a continuous infusion of midazolam and continued morphine dose escalation. DESIGN: Single case report. SETTING: Delivery, monitoring, and titration of morphine and midazolam in the patient's home by a homecare agency. RESULTS: The use of high dosages of morphine (i.e., 500 mg/h) produced myoclonic spasms in this patient, which in turn resulted in increasing pain. To allow for continuation of effective analgesia and to control the myoclonic spasms, an infusion of midazolam was initiated and titrated. The midazolam infusion allowed for continuation of the morphine dosage and also permitted further dosage escalation. As morphine dosages were further escalated, it was also necessary to increase the midazolam infusion to control additional myoclonic spasms. CONCLUSIONS: Use of a concomitant midazolam infusion with high doses of morphine appears to be safe and is an effective means of controlling morphine-induced myoclonus. If further dosage increase of morphine are necessary in this setting, increases in the midazolam infusion also may be required.


This article has been cited by other articles:


Home page
JCOHome page
N. Cherny, C. Ripamonti, J. Pereira, C. Davis, M. Fallon, H. McQuay, S. Mercadante, G. Pasternak, and V. Ventafridda
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report
J. Clin. Oncol., May 1, 2001; 19(9): 2542 - 2554.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1995 by Harvey Whitney Books Company.